SUZHOU, China and HONG KONG and ROCKVILLE, Md., May 22, 2019 /PRNewswire/ — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced the presentation of new clinical data for its investigational apoptosis-targeted drug candidates at the 55th Annual Meeting of the American Read More ›

ROCKVILLE, M.D. and HONG KONG, April 8, 2019 /PRNewswire/ — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B and age-related diseases, today announced that it has entered into a strategic collaboration with Shanghai Junshi Biosciences Co., Ltd. to explore the synergies of Ascentage’s Inhibitor of Apoptosis Proteins Read More ›

ROCKVILLE, MD and HONG KONG, CHINA— March 26th, 2019—Ascentage Pharma, globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases s, today announced that research results of its pipeline of small molecule therapeutics will be presented at the 2019 American Association for Cancer Research (AACR) annual meeting in Atlanta, Read More ›

ROCKVILLE, Md. and HONG KONG, March 18, 2019 /PRNewswire/— Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the appointment of Thomas J. Knapp as Senior Vice President, General Counsel. Mr. Knapp has over 30 years of corporate legal experience, with expertise in the biopharmaceutical Read More ›

Rockville, Maryland and Hong Kong—February 14, 2019— Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the appointment of Jeff Kmetz as Chief Business Officer. Mr. Kmetz has over 25 years of global pharmaceutical and biotechnology industry experience, most recently serving as Chief Business Officer Read More ›

Rockville, Maryland and Hong Kong—January 8, 2019—Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that Unity Biotechnology, Inc. (Nasdaq:UBX) has selected one of Ascentage’s compounds as its lead development candidate in its ophthalmology pipeline to advance into further preclinical studies to enable an Investigational Read More ›

Rockville, MD and Hong Kong, and Houston—January 6, 2019—Ascentage Pharma Group, Inc., and The University of Texas MD Anderson Cancer Center today announced a five-year strategic collaboration agreement to advance the development of five potential new cancer therapies. The alliance is aimed at developing novel cancer therapeutics based upon Ascentage’s proprietary Protein-Protein Interaction drug discovery Read More ›

ROCKVILLE, Md. and SUZHOU, China, — December 19, 2018 — Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that it has entered into a strategic collaboration with Genor Biopharma Co. Ltd. (“Genor”). As part of the agreement, the companies will explore the synergies of Ascentage’s MDM2-p53 inhibitor, APG-115, and Genor’s Read More ›

SAN DIEGO, CA–December 3, 2018–Ascentage Pharma, a clinical-stage biopharmaceutical company dedicated to the development of novel therapies for the treatment of cancers, hepatitis B and aging-related diseases, today announced data from a Phase 1 clinical study of its novel BCR-ABL inhibitor, HQP1351, in patients with Tyrosine Kinase Inhibitor (TKI)-refractory chronic myelogenous leukemia (CML) at the Read More ›

SUZHOU, China and HONG KONG and ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ – Ascentage Pharma, a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies for the treatment of cancers, hepatitis B and aging-related diseases, announced today that the Company will present clinical data of its novel BCR-ABL inhibitor HQP1351 in the upcoming 60th Annual Meeting of the American Society of Read More ›